» Articles » PMID: 36851576

SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion Via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2023 Feb 28
PMID 36851576
Authors
Affiliations
Soon will be listed here.
Abstract

Proprotein convertases activate various envelope glycoproteins and participate in cellular entry of many viruses. We recently showed that the convertase furin is critical for the infectivity of SARS-CoV-2, which requires cleavage of its spike protein (S) at two sites: S1/S2 and S2'. This study investigates the implication of the two cholesterol-regulating convertases SKI-1 and PCSK9 in SARS-CoV-2 entry. The assays used were cell-to-cell fusion in HeLa cells and pseudoparticle entry into Calu-3 cells. SKI-1 increased cell-to-cell fusion by enhancing the activation of SREBP-2, whereas PCSK9 reduced cell-to-cell fusion by promoting the cellular degradation of ACE2. SKI-1 activity led to enhanced S2' formation, which was attributed to increased metalloprotease activity as a response to enhanced cholesterol levels via activated SREBP-2. However, high metalloprotease activity resulted in the shedding of S2' into a new C-terminal fragment (S2″), leading to reduced cell-to-cell fusion. Indeed, S-mutants that increase S2″ formation abolished S2' and cell-to-cell fusion, as well as pseudoparticle entry, indicating that the formation of S2″ prevents SARS-CoV-2 cell-to-cell fusion and entry. We next demonstrated that PCSK9 enhanced the cellular degradation of ACE2, thereby reducing cell-to-cell fusion. However, different from the LDLR, a canonical target of PCSK9, the C-terminal CHRD domain of PCSK9 is dispensable for the PCSK9-induced degradation of ACE2. Molecular modeling suggested the binding of ACE2 to the Pro/Catalytic domains of mature PCSK9. Thus, both cholesterol-regulating convertases SKI-1 and PCSK9 can modulate SARS-CoV-2 entry via two independent mechanisms.

Citing Articles

Cholesterol and Cholesterol-Lowering Medications in COVID-19-An Unresolved Matter.

Grewal T, Nguyen M, Buechler C Int J Mol Sci. 2024; 25(19).

PMID: 39408818 PMC: 11477656. DOI: 10.3390/ijms251910489.


Aprotinin (I): Understanding the Role of Host Proteases in COVID-19 and the Importance of Pharmacologically Regulating Their Function.

Padin J, Perez-Ortiz J, Redondo-Calvo F Int J Mol Sci. 2024; 25(14).

PMID: 39062796 PMC: 11277036. DOI: 10.3390/ijms25147553.


Proprotein Convertase Subtilisin/Kexin Type 9 Induction in COVID-19 Is Poorly Associated with Disease Severity and Cholesterol Levels.

Mester P, Amend P, Schmid S, Wenzel J, Horing M, Liebisch G Infect Dis Rep. 2024; 16(4):593-607.

PMID: 39051245 PMC: 11270413. DOI: 10.3390/idr16040045.


Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection.

Muzammil K, Hosseini Hooshiar M, Varmazyar S, Omar T, Karim M, Aadi S Microb Cell Fact. 2024; 23(1):90.

PMID: 38528584 PMC: 10962113. DOI: 10.1186/s12934-024-02355-8.


Cholesterol and COVID-19-therapeutic opportunities at the host/virus interface during cell entry.

Grewal T, Nguyen M, Buechler C Life Sci Alliance. 2024; 7(5).

PMID: 38388172 PMC: 10883773. DOI: 10.26508/lsa.202302453.


References
1.
Johnson B, Xie X, Bailey A, Kalveram B, Lokugamage K, Muruato A . Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature. 2021; 591(7849):293-299. PMC: 8175039. DOI: 10.1038/s41586-021-03237-4. View

2.
Raini S, Takamatsu Y, Dumre S, Urata S, Mizukami S, Moi M . The novel therapeutic target and inhibitory effects of PF-429242 against Zika virus infection. Antiviral Res. 2021; 192:105121. DOI: 10.1016/j.antiviral.2021.105121. View

3.
Saavedra Y, Day R, Seidah N . The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem. 2012; 287(52):43492-501. PMC: 3527936. DOI: 10.1074/jbc.M112.394023. View

4.
Luna P, Perez M, Castellar-Lopez J, Chang A, Montoya Y, Bustamante J . Potential of Angiotensin-(1-7) in COVID-19 Treatment. Curr Protein Pept Sci. 2022; 24(1):89-97. DOI: 10.2174/1389203724666221130140416. View

5.
Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View